Drug Profile
Vadimezan - Antisoma/Novartis
Alternative Names: 5,6-MeXAA; AS 1404; ASA 404; Dimethylxanthenone acetic acid; DMXAA; NSC-640488; R1564Latest Information Update: 04 May 2016
Price :
$50
*
At a glance
- Originator Auckland Cancer Society Research Centre
- Developer Antisoma; Auckland Cancer Society Research Centre; Novartis
- Class Antineoplastics; Small molecules; Xanthones
- Mechanism of Action Vascular disrupting agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Urogenital cancer
Most Recent Events
- 11 Nov 2010 Discontinued - Phase-II for Prostate cancer in Australia (IV)
- 11 Nov 2010 Discontinued - Phase-II for Prostate cancer in USA (IV)
- 11 Nov 2010 Discontinued - Phase-II for Urogenital cancer in USA (IV)